FAS Investigates Teva and Grotex for Alleged Unfair Competition Over Generic Apixaban Launch
核心洞察
Russia's Federal Antimonopoly Service (FAS) has identified signs of unfair competition in the introduction of generic drugs "Apixanta" and "Apiklis" (INN Apixaban).
Pfizer Innovations and a representative of the patent holder for apixaban filed the complaint, alleging the generics entered civil circulation before the Eliquis patent expired.
The FAS will examine whether Teva (搜索) and Grotex (搜索) (Solopharm (搜索)) violated the Law on Protection of Competition.
Russia's Federal Antimonopoly Service (FAS) has identified signs of unfair competition in the introduction of two generic apixaban products, "Apixanta" and "Apiklis," according to a statement from the department. The investigation follows a complaint filed by Pfizer Innovations and a representative of the patent holder for the active substance apixaban.
The applicants reported that the pharmaceutical companies Teva (搜索) and Grotex (搜索) had introduced the reproduced medicines Apixanta and Apiklis (INN Apixaban) into civil circulation before the expiration of the patent for the original drug Eliquis. In response, the FAS will check the actions of Teva and Grotex for compliance with the provisions of the Law on Protection of Competition.
The dispute concerns apixaban, a widely used anticoagulant and the active ingredient in Eliquis, which is marketed by Pfizer. The complaint alleges that the generic versions were launched prematurely, raising questions about patent protection and market-entry timing for the branded therapy.
Teva (搜索) is a multinational pharmaceutical company headquartered in Petah Tikva, Israel, specializing in the production of generics and, to a lesser extent, its own drugs. Grotex (搜索), operating under the Solopharm (搜索) brand, is a full-service Russian pharmaceutical company specializing in the development and manufacture of medicines, medical devices, and dietary supplements.
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation with headquarters in New York, USA. The FAS investigation will determine whether the actions of Teva (搜索) and Grotex (搜索) comply with Russian competition law, with potential implications for the timing and legality of generic apixaban market entry.